Carcell
|
Year Established:
2021 |
|
|
Website:
carcell.com |
|
|
Company Type:
New Startup (0-1M TTM Revenue) |
Carcell is a global biotech company empowering drug delivery through red cell therapeutics and lipid nanoparticles (LNPs). As a fellow biotech company, we understand the intricacies of making and developing a drug. As such, we offer a variety of licensing opportunities, research collaborations and contract services depending on your needs to bring your preclinical pipelines all the way to the finish line.
Carcell has a rapidly growing vault of > 1,500 novel and proprietary ionizable lipids. We test the potency and distribution of these lipids in mice and compare them to commercial benchmarks such as ALC-0315, SM-102 and MC3. The top performers are subjected to further scrutiny such as tolerability studies and freedom-to-operate (FTO) analysis. Some of these lipids are available for licensing (with or without co-development).
Carcell also has a suite of end-to-end LNP services for your experimental needs. Our LNP services include:
1. Lipid synthesis
2. Lipid screening (pre-curated or customized panels)
3. LNP formulation
4. LNP optimization
5. In vivo testing of LNP
6. Toxicological evaluation of LNP
Contact us to find out more!
| Site | Badges | |
|---|---|---|
| Carcell LNP Lab (Shanghai) #166 Meiyue Road, Blk 122, Level 2, Shanghai Pilot Free-Trade Zone Shanghai, Shanghai, 201208 China | ||
| Carcell Therapeutics (Singapore) 21 Changi South Street 1 Singapore, Singapore, 486777 Singapore | ||
Get started
If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here. To order products instantly, request access below.